Evidence map›Paper›PMID 42806519›Full record

Observational studyCancer medicine2026

Multi-Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM.

Yuqing Feng, Martin Yi, Catherine C Aftandilian, Melissa P Beauchemin, Christine Cunningham, David DeStephano, Rhea K Khurana, Emily Larimer, Jennifer Oberg, Benjamin L May and 8 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuqing FengChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0000-9174-8935
Martin YiChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Catherine C AftandilianDepartment of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.
Melissa P BeaucheminColumbia University School of Nursing/Herbert Irving Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-4058-1586
Christine CunninghamDepartment of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0001-6802-7355
David DeStephanoColumbia University School of Nursing/Herbert Irving Cancer Center, New York, New York, USA.
Rhea K KhuranaColumbia University School of Nursing/Herbert Irving Cancer Center, New York, New York, USA.ORCID https://orcid.org/0009-0008-5464-5548
Emily LarimerBen Towne Center for Childhood Cancer and Blood Disorders Research, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Jennifer ObergDepartment of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-9135-3391
Benjamin L MayDepartment of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
Keith MorseDepartment of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.
Karthik NatarajanData Sciences Unit, Columbia University, New York, New York, USA.ORCID https://orcid.org/0000-0002-9066-9431
David NoydBen Towne Center for Childhood Cancer and Blood Disorders Research, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-3465-5000
Victoria SoucekBen Towne Center for Childhood Cancer and Blood Disorders Research, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0009-0003-0255-6344
Yujie ChenChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Adam YanChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-8300-3095
Lin Lawrence GuoChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-2965-8442
Lillian SungChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0951-3091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOpioid use in pediatric oncology is poorly characterized. The primary objective was to describe opioid administration or prescription patterns in pediatric oncology patients.

methodsIn this multi-center retrospective study conducted across three sites, we included patients aged 0-19 years with a malignant neoplastic disease who received their first chemotherapy between January 2019 and March 2024. Data were extracted from each site's Observational Medical Outcomes Partnership Common Data Model. We described patient characteristics based on: (1) first opioid administration or prescription, overall and for each specific opioid; and (2) all opioid administrations or prescriptions, overall and for each specific opioid. We also evaluated variability in opioid and naloxone use.

resultsOf 2903 pediatric patients with cancer, 2707 (93.2%) were administered or prescribed at least one opioid. Among these patients, fentanyl was the most common (92.4%), followed by morphine (68.7%), hydromorphone (55.3%), and oxycodone (38.6%). Across centers, the proportion of patients receiving fentanyl ranged from 90.9% to 94.9%, morphine from 34.0% to 89.2%, oxycodone from 0.9% to 76.1%, and naloxone from 2.4% to 29.5%. Overall, 10.9% were administered or prescribed naloxone, but among 169 methadone patients, 43.5% were administered or prescribed it. Of the 153,849 total opioid administrations or prescriptions, 22.4% occurred more than 12 months after initiating chemotherapy.

conclusionsAmong pediatric patients with cancer who receive chemotherapy, 93.2% were administered or prescribed at least one opioid; fentanyl was the most common. There was heterogeneity in opioid choice and naloxone use across sites. These findings lay preliminary groundwork for understanding opioid use patterns and identifying potential areas for practice improvement in pediatric oncology.

Indexed as

Analgesics, OpioidCancer PainNeoplasmsPractice Patterns, Physicians'AdolescentChildChild, PreschoolDrug PrescriptionsFemaleHumansInfantInfant, NewbornMaleMorphineRetrospective StudiesYoung AdultAnalgesics, OpioidMorphineOMOP common data modeloncologyopioidpediatric

Identifiers

PMID42806519
PMCPMC13620299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.